Peter Joel Hosein, MBBS

Peter Hosein practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Peter Hosein's NPI, 1154531838, was assigned on May 23, 2007. Peter Hosein graduated from University of the West Indies Faculty of Medicine in 2001. Peter Hosein holds Florida license ME106120.

Peter Hosein's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Peter Hosein's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Peter Hosein is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Peter Hosein practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Peter Hosein's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Peter Hosein is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Peter Hosein's licenses on file in 2 states: Florida and Kentucky.

Dmand AI lists breast cancer, colorectal cancer, lymphoma and multiple myeloma among the conditions Peter Hosein treats.

CMS data shows 839 Medicare services from Peter Hosein across 5 procedure codes in 2024, for 128 Medicare patients. Medicare paid $57,114 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 128 Medicare patients who saw Peter Hosein in 2024. The largest group is 65 to 74, with 61 patients. 63% of them have high blood pressure, and 62% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Peter Hosein's median patient age at 69, with 53% women.

In 2024, Peter Hosein wrote 690 Medicare Part D claims for 96 patients. 71% of them were for generic drugs. CMS names the drug for 341 of them, across 16 drugs with 11 or more claims each, at $331,273 in total drug cost. In 2023, CMS named 747 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Peter Hosein for performance year 2024, reported as part of a group. Peter Hosein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Peter Hosein as offering telehealth.

Dmand AI links 71 papers to Peter Hosein, published from 2011 to 2025. 2016 was the busiest year, with 6. The most frequent topics are Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Adenocarcinoma. Peter Hosein has published most often in JCO Precis Oncol. Peter Hosein's most frequent co-authors are Jashodeep Datta, MD, Izidore Lossos, MD and Nipun B. Merchant, MD.

Dmand AI links Peter Hosein to 5 clinical trials, 3 of them phase 2 studies. Conditions studied include Carcinoma, Hepatocellular, Epstein-Barr Virus Infections and Gallbladder Neoplasms. University of Miami sponsors the most, 2.

CMS Open Payments shows 54 general payments to Peter Hosein from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. AngioDynamics, Inc. paid the most, $18,466.

Peter Hosein graduated from University of the West Indies Faculty of Medicine in 2001. Peter Hosein is a member of ASCO.

Peter Hosein is in network with 11 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.